News

This is the second program between the two companies under an agreement signed in August 2006. In this new collaboration, BioFocus DPI will perform medicinal chemistry, computational chemistry

Viventia is currently enrolling patients in its phase III clinical trial that is expected to complete accrual by the end of 2007. The combination of Proxinium with cisplatin,

Under the terms of the royalty bearing agreements, Carrington will supply its raw material, acemannan hydrogel, to Primus for use in topical prescription products. In exchange for guaranteed

Sales rose to CHF11.4 billion ($9.42 billion), between January and March. As a result Roche anticipates continued strong growth for 2007. Overall the pharmaceuticals division grew by 20%

According to the study, GX15-070 demonstrated potent single agent activity against acute lymphoblastic leukemia (ALL) blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxic drugs. GX15-070

The phase Ib trial was designed to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PRX-07034, a 5-HT6 antagonist, administered orally once-daily for 28 days in a population

The company said it has sought scientific advice on final aspects of the trial design from regulatory authorities in Europe and the US and expects to initiate patient

The Japanese Ministry of Health, Labor and Welfare has granted this approval following a recommendation, made in July 2005 by the Investigational Committee for Usage of Unapproved Drugs,

The preclinical study conducted at the University of California Irvine, with US bioscience company Martek’s support, used genetically modified mice. It is the first study to show that